Literature DB >> 8942435

Family history and prostate cancer risk.

S M Lesko1, L Rosenberg, S Shapiro.   

Abstract

The authors examined the relation between family history of prostate cancer and the risk of this cancer in a population-based case-control study conducted in Massachusetts between December 1992 and October 1994. Cases were all incident cases of prostate cancer in men younger than 70 years (n = 563); controls were men with no history of the disease matched to the cases on age and town of residence (n = 703). Prostate cancer risk was increased among men who reported a history of this cancer in either their fathers or brothers (odds ratio (OR) = 2.3, 95% confidence interval (CI) 1.7-3.3). Risk varied with the number of relatives affected and their relationship to the case. For a history of prostate cancer in one relative, the OR was 2.2 (95% CI 1.5-3.2); if two or more relatives were affected, it was 3.9 (95% CI 1.7-5.2). For prostate cancer in the father, the OR was 1.9 (95% CI 1.2-3.0); for prostate cancer in a brother, it was 3.0 (95% CI 1.8-4.9). Risk was inversely related to the subject's age and to age at diagnosis of prostate cancer in his affected relative. Among probands younger than 60 years, the OR was 5.3 (95% CI 2.5-12); for those 60-64 years of age, the OR was 2.7 (95% CI 1.3-5.5); and for those 65 years of age and older, the OR was 1.6 (95% CI 1.0-2.5). For prostate cancer diagnosed in a relative before age 65, the OR was 4.1 (95% CI 2.3-7.3); for detection of the disease after age 74, the OR was 0.76 (95% CI 0.38-1.5). The association was present both among men with local and advanced stage disease and among men whose prostate cancer was detected either by screening or because of symptoms. These data provide evidence that after controlling for diet and other potential confounders, familial factors are significantly associated with the risk of prostate cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8942435     DOI: 10.1093/oxfordjournals.aje.a008876

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  21 in total

1.  Segregation analyses of 1,476 population-based Australian families affected by prostate cancer.

Authors:  J Cui; M P Staples; J L Hopper; D R English; M R McCredie; G G Giles
Journal:  Am J Hum Genet       Date:  2001-04-11       Impact factor: 11.025

2.  Psychological and screening profiles of first-degree relatives of prostate cancer patients.

Authors:  S M Miller; M A Diefenbach; L K Kruus; D Watkins-Bruner; G E Hanks; P F Engstrom
Journal:  J Behav Med       Date:  2001-06

3.  Prostate cancer survival in Trinidad: Is PSA a prognostic factor?

Authors:  Kameel Mungrue; Suresh Moonan; Maryam Mohammed; Saara Hyatali
Journal:  Can Urol Assoc J       Date:  2011-11-02       Impact factor: 1.862

4.  Polymorphisms of TP53 codon 72 with prostate carcinoma risk: a meta-analysis.

Authors:  Jing Zhang; Wen-Lei Zhuo; Ying Zheng; Yun-Song Zhang
Journal:  Med Oncol       Date:  2009-06-05       Impact factor: 3.064

5.  Is prostate cancer a Lynch syndrome cancer?

Authors:  Aung Ko Win
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

Review 6.  Prostate cancer: 3. Individual risk factors.

Authors:  R P Gallagher; N Fleshner
Journal:  CMAJ       Date:  1998-10-06       Impact factor: 8.262

Review 7.  Association of p53 codon 72 polymorphism with prostate cancer: an update meta-analysis.

Authors:  Yu Lu; Yanqiong Liu; Jie Zeng; Yu He; Qiliu Peng; Yan Deng; Jian Wang; Li Xie; Taijie Li; Xue Qin; Shan Li
Journal:  Tumour Biol       Date:  2014-02-01

8.  Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium.

Authors:  Michele L Coté; Mei Liu; Stefano Bonassi; Monica Neri; Ann G Schwartz; David C Christiani; Margaret R Spitz; Joshua E Muscat; Gad Rennert; Katja K Aben; Angeline S Andrew; Vladimir Bencko; Heike Bickeböller; Paolo Boffetta; Paul Brennan; Hermann Brenner; Eric J Duell; Eleonora Fabianova; John K Field; Lenka Foretova; Søren Friis; Curtis C Harris; Ivana Holcatova; Yun-Chul Hong; Dolores Isla; Vladimir Janout; Lambertus A Kiemeney; Chikako Kiyohara; Qing Lan; Philip Lazarus; Jolanta Lissowska; Loic Le Marchand; Dana Mates; Keitaro Matsuo; Jose I Mayordomo; John R McLaughlin; Hal Morgenstern; Heiko Müeller; Irene Orlow; Bernard J Park; Mila Pinchev; Olaide Y Raji; Hedy S Rennert; Peter Rudnai; Adeline Seow; Isabelle Stucker; Neonila Szeszenia-Dabrowska; M Dawn Teare; Anne Tjønnelan; Donatella Ugolini; Henricus F M van der Heijden; Erich Wichmann; John K Wiencke; Penella J Woll; Ping Yang; David Zaridze; Zuo-Feng Zhang; Carol J Etzel; Rayjean J Hung
Journal:  Eur J Cancer       Date:  2012-03-19       Impact factor: 9.162

9.  In vitro and in vivo model systems used in prostate cancer research.

Authors:  David Cunningham; Zongbing You
Journal:  J Biol Methods       Date:  2015

10.  Obesity, age, ethnicity, and clinical features of prostate cancer patients.

Authors:  Victor J Wu; Darren Pang; Wendell W Tang; Xin Zhang; Li Li; Zongbing You
Journal:  Am J Clin Exp Urol       Date:  2017-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.